{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059498","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.665338+00:00","generated_at":"2026-06-02T01:03:54.244975+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer","bullets":["Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.","Previously Head of Clinical Development at Laronde (now Sail Bio) and Executive Director at Ionis Pharmaceuticals.","Over 10 years of neurology and rare disease clinical development experience, including global approvals.","M.D. from University of Maryland School of Medicine with fellowship in Neuroimmunology & Multiple Sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059498","json":"https://secwatch.observer/filing/0000950170-24-059498.json","markdown":"https://secwatch.observer/filing/0000950170-24-059498.md","text":"https://secwatch.observer/filing/0000950170-24-059498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/0000950170-24-059498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/krro-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:54.244975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}